Next Article in Journal
Mutational Landscape of Alzheimer’s Disease and Frontotemporal Dementia: Regional Variances in Northern, Central, and Southern Italy
Previous Article in Journal
Investigating the Effectiveness of Ceragenins against Acinetobacter baumannii to Develop New Antimicrobial and Anti-Adhesive Strategies
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 25
Issue 13
10.3390/ijms25137037
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Origin and Roles of Alanine and Glutamine in Gluconeogenesis in the Liver, Kidneys, and Small Intestine under Physiological and Pathological Conditions

by
Milan Holeček
Department of Physiology, Faculty of Medicine, Charles University, 500 03 Hradec Kralove, Czech Republic
Int. J. Mol. Sci. 2024, 25(13), 7037; https://doi.org/10.3390/ijms25137037
Submission received: 29 May 2024 / Revised: 21 June 2024 / Accepted: 25 June 2024 / Published: 27 June 2024
(This article belongs to the Special Issue Amino Acids and Related Compounds in Health and Disease)
Browse Figures
Versions Notes

Abstract

:
Alanine and glutamine are the principal glucogenic amino acids. Most originate from muscles, where branched-chain amino acids (valine, leucine, and isoleucine) are nitrogen donors and, under exceptional circumstances, a source of carbons for glutamate synthesis. Glutamate is a nitrogen source for alanine synthesis from pyruvate and a substrate for glutamine synthesis by glutamine synthetase. The following differences between alanine and glutamine, which can play a role in their use in gluconeogenesis, are shown: (i) glutamine appearance in circulation is higher than that of alanine; (ii) the conversion to oxaloacetate, the starting substance for glucose synthesis, is an ATP-consuming reaction for alanine, which is energetically beneficial for glutamine; (iii) most alanine carbons, but not glutamine carbons, originate from glucose; and (iv) glutamine acts a substrate for gluconeogenesis in the liver, kidneys, and intestine, whereas alanine does so only in the liver. Alanine plays a significant role during early starvation, exposure to high-fat and high-protein diets, and diabetes. Glutamine plays a dominant role in gluconeogenesis in prolonged starvation, acidosis, liver cirrhosis, and severe illnesses like sepsis and acts as a substrate for alanine synthesis in the small intestine. Interactions among muscles and the liver, kidneys, and intestine ensuring optimal alanine and glutamine supply for gluconeogenesis are suggested.

1. Introduction

Gluconeogenesis is a metabolic pathway of glucose synthesis from non-carbohydrate substances essential for maintaining glycemia during starvation, prolonged exercise, and a carbohydrate-deficient diet. It contributes to increased glucose levels in diabetes and disorders associated with insulin resistance. The primary substrates are lactate, glycerol, and glucogenic amino acids. Glucogenic amino acids are mostly those that can be converted to oxaloacetate, a substance that initiates gluconeogenesis in a reaction catalyzed by phosphoenolpyruvate carboxykinase (PEPCK). Gluconeogenesis is regulated by several translational and posttranslational mechanisms [1,2,3,4]. In most conditions, but not all, gluconeogenesis is stimulated synergistically by increasing the supply of substrates and catabolic hormones, particularly glucagon, catecholamines, and cortisol.
It has been believed for many years that alanine is the primary glucogenic amino acid and that the liver has a central position in gluconeogenesis [5,6]. However, this idea has been challenged by reports demonstrating that glutamine and the kidneys have much more significance in glucose homeostasis than was expected [3,7,8,9,10] and suggesting that because the main substrate for alanine synthesis is pyruvate formed during glycolysis, alanine should instead be considered as a substance that ensures glucose recycling between the liver and muscles via the “alanine cycle,” rather than a substrate for gluconeogenesis [11,12,13]. Although there are many data in the scientific literature, the roles of alanine and the liver on one side and glutamine and kidneys on the other in maintaining glucose homeostasis are not yet fully understood. Furthermore, several lines of evidence support the view that gluconeogenesis also occurs in the small intestine [4,14,15].
This study aimed to explain the pathways of endogenous production of alanine and glutamine and clarify their roles in gluconeogenesis in the liver, kidneys, and small intestine under various physiological and pathological conditions, including starvation, high-protein and high-fat diets, diabetes, and liver cirrhosis.

2. Sources of Alanine and Glutamine in the Body

Ijms 25 07037 i001
Alanine and glutamine are quantitatively the most important glucogenic amino acids due to their simple conversion to oxaloacetate and much higher concentrations and appearance rates in plasma compared to other glucogenic amino acids. Alanine concentrations (~0.3 mM) and glutamine (~0.6 mM) comprise more than 60% of the free α-amino acid pool in plasma. In healthy humans in a postabsorptive state, plasma alanine’s appearance rate is ~200 µmol/kg per h (~30 g per day) and ~325 µmol/kg per h (~80 g per day) for glutamine [16], which is several times higher than the appearance rates of other amino acids and approximately ten times higher than daily intake of alanine and glutamine in food.

2.1. Alanine and Glutamine Synthesis in Skeletal Muscle

Early studies have demonstrated that the main source of alanine and glutamine in the body is their endogenous synthesis in skeletal muscle and that branched-chain amino acids (BCAAs; valine, leucine, and isoleucine) are a donor of amino nitrogen to 2-oxoglutarate (2-OG) to form glutamate, which is converted by aspartate aminotransferase (AST) to aspartate in the mitochondria [17,18,19,20]. Aspartate is transported to the cytosol via uncoupling protein 2 (UCP2) or aspartate–glutamate carrier 1 (AGC1, aralar 1), a component of the malate–aspartate shuttle [21,22]. In the cytosol, aspartate provides its amino group for the synthesis of glutamate, which acts as the main source of nitrogen for alanine synthesis by alanine aminotransferase (ALT) and a substrate for glutamine synthesis by glutamine synthetase [17]. The primary source of pyruvate for alanine synthesis is glycolysis, and the source of ammonia for glutamine synthesis is the purine–nucleotide cycle [23]. Because aspartate can enter the purine–nucleotide cycle, its amino group originating from the BCAA can also appear as an amide group in glutamine (Figure 1). Alanine is released from muscles through several transporters including ASCT1 and ASCT2, and glutamine is released mainly by LAT1 [24].
BCAA transamination and the production of glutamine and alanine are activated under the condition of increased BCAA supply to BCAA aminotransferase, for instance, with a protein-rich diet, in the initial phase of starvation, during exercise, and in muscle wasting disorders [17]. The ratio between the amount of alanine and glutamine released into the bloodstream depends on the supply of pyruvate and ammonia. If glycolysis is active, alanine is preferentially synthesized and released from muscles, for instance, during fasting, when glycolysis and glycogenolysis are activated in the muscles. In hyperammonemia, e.g., due to liver injury, glutamine synthetase is activated, and glutamine becomes the main product.

2.2. BCAAs Can Be a Source of Carbons for Glutamine sSynthesis

BCAAs can become a source of carbons for glutamine synthesis when branched-chain keto acids (BCKAs) produced in muscles by BCAA aminotransferase are not released into the circulation but oxidized by BCKA dehydrogenase, the rate-limiting enzyme of BCAA catabolism. The branched-chain acyl-CoAs produced by BCKA dehydrogenase are degraded gradually into acetyl-CoA and succinyl-CoA, which can enter the CAC, and their carbons appear in 2-OG, which can be subsequently converted to glutamine via transamination and amidation reactions. The isotopic tracing technique has confirmed the possibility. Incubation of muscles with [U-14C]BCAA, [U-14C]valine, or [U-14C]BCKA demonstrated that the carbons appear in glutamine and glutamate but not alanine [25,26]. The role of the CAC in glutamine synthesis has been shown using incubation of rat diaphragms with [2,3-14C]succinate in which the 14C recovered from alanine was only 2 or 3% of that in glutamine and glutamate [25].
It should be noted that succinate originating from valine or isoleucine can provide four carbons to make a 2-OG molecule, whereas only one carbon can originate from acetyl-CoA produced by leucine or isoleucine catabolism. Acetyl-CoA provides two carbons to oxaloacetate to form citrate (contains six carbons) that is gradually converted to 2-OG made up of five carbons, of which only one is from acetyl-CoA. Assuming simultaneous utilization of all three BCAA, all 2-OG carbons can be derived from BCAAs.
Because BCKA dehydrogenase activity in muscles is very low, BCAAs can become a source of carbon for glutamine synthesis only in certain metabolic conditions in which BCKA dehydrogenase is activated. For instance, in the final stage of starvation, untreated diabetes, severe injury, and sepsis [27,28,29,30].

2.3. Alanine and Glutamine Synthesis in Other Tissues

In addition to muscles, alanine and glutamine can be released from adipose tissue and lungs, glutamine from the brain and liver, and alanine from the small intestine and kidneys. In adipose tissue, alanine and glutamine synthesis is associated with using BCAAs for fat synthesis and stimulated by insulin in a postprandial state [31,32]. In the lungs, glutamine synthetase expression and glutamine production are increased in post-operative conditions, trauma, and sepsis [33]. The main site of glutamine synthesis in the brain is astrocytes [34]. The pathways of glutamine synthesis in the liver by perivenous hepatocytes and alanine synthesis in the small intestine and kidneys are described in the following sections.

3. Alanine and Glutamine Conversion to Oxaloacetate

The pathways of alanine and glutamine conversion to oxaloacetate, the starting substance of gluconeogenesis, differ and can be influenced by various factors (Figure 2).

3.1. Oxaloacetate Synthesis from Alanine

Alanine is converted to oxaloacetate in two steps catalyzed by ALT and pyruvate carboxylase:
Ala + 2-OG ↔ Pyr + Glu
Pyr + CO2 + ATP → OA + ADP + Pi
The highest ALT activities are in the liver, small intestine, muscles, heart, and kidneys [35]. However, a pronounced flux toward pyruvate is only in the liver. High levels of pyruvate carboxylase are in the liver and kidney cortex, lower in other tissues, including the small intestine [36].
For the fate of pyruvate, it is significant that pyruvate carboxylase is allosterically activated by acetyl-CoA and requires ATP, whereas pyruvate dehydrogenase, which ensures pyruvate conversion to acetyl-CoA, is inhibited by NADH. Therefore, pyruvate conversion to oxaloacetate by pyruvate carboxylase will be prioritized over the flux through pyruvate dehydrogenase under conditions of increased β-oxidation due to enhanced supply of acetyl-CoA, NADH, and ATP. This means that gluconeogenesis from pyruvate can be facilitated.

3.2. Oxaloacetate Synthesis from Glutamine

Glutamine is converted to oxaloacetate in three steps catalyzed by glutaminase, glutamate dehydrogenase (GDH) or mitochondrial AST, and enzymes of the CAC:
GlutaminaseGln + H2O → Glu + NH3
GDH or AST Glu + H2O + NAD(P)+ ↔ NH3 + 2-OG + NAD(P)H + H+Glu + OA ↔ Asp + 2-OG
2-OG → OA (CAC)2-OG + NAD+ + FAD+ + H2O ↔ OA + NADH+H++ FADH2 + CO2
Glutaminase exists in two isoforms–hepatic and renal. The hepatic type is expressed in periportal hepatocytes, the brain, and the pancreas. The renal type is abundant in kidneys, brain, intestine, and leucocytes. A drop in pH inhibits the liver type, whereas the renal type is activated [37]. GDH, like glutaminase, also exists in two forms. GDH1, located in the liver, can both remove and release ammonia [38]. GDH2, which shows a lower optimal pH, ensures the flux towards ammonia in the proximal tubules of the kidneys [39]. The flux through mitochondrial AST is driven toward the direction of 2-OG by aspartate–glutamate carrier 1/2 (AGC1/2), which continuously supplies glutamate and protons into mitochondria and removes aspartate. AGC2 (citrin) is strongly expressed in all three gluconeogenic organs [40].
The conversion of 2-OG to oxaloacetate through the CAC is ensured by oxoglutarate dehydrogenase, succinate dehydrogenase, fumarase, and malate dehydrogenase and is associated with the synthesis of NADH and FADH2. Therefore, (i) the conversion of glutamine to oxaloacetate can result in an increased ATP formation, and (ii) the flux of 2-OG toward oxaloacetate via the CAC can be inhibited by the increased supply of NADH and FADH2 from other sources, for instance, due to enhanced oxidation of fatty acids after increased dietary intake of lipids.

3.3. Oxaloacetate Transport from the Mitochondria into the Cytosol

Because the inner mitochondrial membrane is impermeable to oxaloacetate, a special form of oxaloacetate delivery into the cytosol, where the enzymes of gluconeogenesis are located, is required. The main is probably the form of aspartate synthesized by the mitochondrial AST (OA + Glu → Asp + 2-OG) and transported into the cytosol through AGC2 or UCP2 [21,40]. In the cytosol, aspartate is converted to oxaloacetate by the cytosolic form of AST (Asp + 2-OG → OA + Glu). Transport in the form of malate, an option noted in textbooks of biochemistry, is less likely [41].

4. Gluconeogenesis from Alanine and Glutamine in Liver, Kidneys, and Small Intestine

Most studies on the use of alanine and glutamine for gluconeogenesis conclude that alanine is the primary amino acid for gluconeogenesis in the liver, whereas glutamine plays the leading role in kidneys and small intestine [4,8,42,43].

4.1. Gluconeogenesis from Alanine and Glutamine in the Liver

In the liver, the enzymes of gluconeogenesis are expressed together with enzymes of the urea cycle in periportal hepatocytes (the peripheral part of the liver lobule), and it is consensus that hepatic gluconeogenesis from amino acids is associated with urea synthesis [44,45,46].
For an understanding of the coupling of gluconeogenesis with the urea cycle, it is important to realize that one of two nitrogen atoms in the urea molecule originates from ammonia and the second from aspartate and that the entry of ammonia and aspartate into the urea cycle must be linked. In Figure 3, it is shown that aspartate delivered into the cytosol reacts with citrulline, which contains nitrogen originating from ammonia, to enter the urea cycle in the form of argininosuccinate, which is degraded to arginine and fumarate. Fumarate released from the urea cycle is via malate converted to oxaloacetate, from which gluconeogenesis begins. Therefore, increased flux through the urea cycle, driven by the ammonia in the mitochondria and aspartate in the cytosol, can stimulate gluconeogenesis.

4.1.1. Why Is Alanine a Preferred Substrate for Hepatic Gluconeogenesis?

Alanine likely plays a more important role in hepatic gluconeogenesis when compared with glutamine because the conditions for glutamine conversion to oxaloacetate are not optimal. In the liver, the direction of the flux through GDH1 depends on several factors and, in most conditions, it is directed toward conversion of 2-OG to glutamate (2-OG + NH3 + NAD(P)H + H+ → Glu + H2O + NAD(P)+) [38,39]. Therefore, the amount of 2-OG that can enter the CAC to form oxaloacetate is limited. The suggestion is supported by the observation that after administration of L-[13N] glutamate into the portal vein, most labels incorporated into aspartate, and a much smaller amount appeared in ammonia [47]. On the other hand, glutamate synthesized by GDH1 can favor the use of alanine for gluconeogenesis by its reaction with oxaloacetate of alanine origin to ensure its transport into the cytosol in the form of aspartate (Figure 3).
Substantial glutamine uptake and alanine release by the small intestine, resulting in increased alanine and decreased glutamine levels in the portal vein that supplies most of the blood to the liver, can also play a role in the preferred use of alanine for hepatic gluconeogenesis [14,48,49,50]. In net balance studies in humans, liver uptake of alanine has been shown to account for ~50% of total amino acid uptake, whereas minimal uptake has been observed with glutamine [42,43].

4.1.2. The Role of Perivenous Hepatocytes

In the central part of the liver lobule (perivenous hepatocytes), GDH1 is not found together with glutaminase but with glutamine synthetase and enables ammonia detoxification to glutamine [39,51,52]. It has been shown that a drop in pH inhibits glutaminase and carbamoyl phosphate synthetase, and subsequent ammonia detoxification into urea in periportal hepatocytes, whereas ammonia detoxification into glutamine and glutamine release into the blood increase in perivenous hepatocytes [37,51,53,54]. Glutamine production by perivenous hepatocytes may help to fulfill the increased needs for glutamine by the kidneys during acidosis and reduce the loss of nitrogen in protein-wasting conditions, like prolonged starvation (Figure 4).

4.2. Gluconeogenesis from Glutamine in Kidneys

In the kidneys, gluconeogenesis and glucose release into circulation occurs in the proximal tubules of the renal cortex and accounts for 15–40% of endogenous glucose production in humans in postabsorptive states and increases substantially during starvation and acidosis [7,8,55,56,57]. Human and animal data examining renal arteriovenous differences and the incorporation of gluconeogenic precursors into glucose show that lactate and glutamine are the most important, glycerol less so, and alanine, which the kidneys release into the blood, is the least important [7,8,43,48,58,59].
It has been shown that glutamine accounts for up to 20% of all renal gluconeogenesis in the postabsorptive state, and there is a close relationship with ammonia and bicarbonate ions formation [7,8,60]. Glutamine, which enters the tubular cells by several transporters, including B0AT1 on the luminal side and Na+/H+-dependent system SNAT3 on the basolateral side [61], is rapidly hydrolyzed by the renal type of glutaminase, which is activated when acidity rises [37]. Both glutamate dehydrogenase and aminotransferase pathways are involved in forming 2-OG, which is converted to oxaloacetate by enzymes of the CAC. Under acidosis, because GDH2 is activated by decreased pH, the flux through the glutamate dehydrogenase pathway can be more pronounced (Figure 5).

Alanine Metabolism in Kidneys

Unlike the liver, the role of alanine as a substrate for gluconeogenesis seems to be of little significance in the kidneys [48,58]. However, there are several remarkable links between the metabolism of alanine, glutamine, and ammonia. For instance, when plasma alanine is elevated, conversion of this amino acid to ammonia increases, whereas glutamine administration increases renal production of alanine [60,62]. The increase in ammonia production by increased alanine levels is apparently due to alanine transamination with 2-OG to form glutamate, which is subsequently deaminated to liberate ammonia. The rise in alanine production by increased glutamine levels can be explained by the increased supply of glutamate, which acts as a nitrogen donor for alanine synthesis by ALT in the cytosol. Hence, the balance between alanine production and utilization in kidneys is dependent, at least in part, on the concentrations of the reactants. In most conditions, the net balance is towards alanine synthesis [48,58].

4.3. Gluconeogenesis from Glutamine in the Small Intestine (Figure 6)

Animal and human studies have demonstrated that the small intestine produces and releases glucose into venous blood in postabsorptive and fasting states, with a high-protein diet, and in diabetes [4,14,15,63,64]. Glutamine is the primary substrate. Enterocytes of the small intestine contain very high glutaminase activities [65,66], and a significant increase in glucose radioactivity has been observed in the mesenteric vein in fasting and diabetic rats infused with L-[U-14C]glutamine. In contrast, a very small or insignificant increase was found after infusion of [U-14C]lactate, [U-14C]alanine, and [2-13C]glycerol in fasting rats [64].
Glutamine is transported into enterocytes by B0AT1 from the intestinal lumen and several transporters, notably SNAT1, SNAT2, and SNAT4, from the blood [24]. Glutamate produced by glutaminase is converted to oxaloacetate by transamination, not the GDH pathway. That means that 2-OG is formed gradually by glutaminase and AST reactions and then converted through CAC enzymes to oxaloacetate, which contains carbons originating from glutamine. The opinion is based on the relatively low expression of GDH in enterocytes and observations that intestinal glutamine oxidation is inhibited by aminooxyacetate, a known aminotransferase inhibitor [38,67,68].
Ijms 25 07037 g006
Figure 6. The role of glutamine in gluconeogenesis and alanine synthesis in enterocytes. The main pathway by which the carbon skeleton of glutamine is converted to OA is depicted on the right side. 1, ALT (cytosolic); 2, pyruvate carboxylase; 3, AST (mitochondrial); 4, AST (cytosolic); 5, glutaminase; 6, GDH1; 7, enzymes converting 2-OG to malate; 8, malate dehydrogenase (mitochondrial); 9, PEPCK; 10, malate dehydrogenase (cytosolic); 11, ALT (mitochondrial); 12, pyruvate kinase; 13, lactate dehydrogenase. Abbreviations: AGC2, aspartate–glutamate carrier 2; B0AT1, broad neutral amino acid transporter 1; CAC, citric acid cycle; EAAT, excitatory amino acid transporters; GLUT, glucose transporter; LAT, large neutral amino acid transporter; Mal, malate; MCT, monocarboxylate transporter; OA, oxaloacetate; OGC, oxoglutarate carrier; PC, pyruvate carrier; PEP, phosphoenolpyruvate; Pyr, pyruvate; SGLT, sodium–glucose-linked transporter; SNAT, sodium neutral amino acid transporter; 2-OG, 2-oxoglutarate.
Figure 6. The role of glutamine in gluconeogenesis and alanine synthesis in enterocytes. The main pathway by which the carbon skeleton of glutamine is converted to OA is depicted on the right side. 1, ALT (cytosolic); 2, pyruvate carboxylase; 3, AST (mitochondrial); 4, AST (cytosolic); 5, glutaminase; 6, GDH1; 7, enzymes converting 2-OG to malate; 8, malate dehydrogenase (mitochondrial); 9, PEPCK; 10, malate dehydrogenase (cytosolic); 11, ALT (mitochondrial); 12, pyruvate kinase; 13, lactate dehydrogenase. Abbreviations: AGC2, aspartate–glutamate carrier 2; B0AT1, broad neutral amino acid transporter 1; CAC, citric acid cycle; EAAT, excitatory amino acid transporters; GLUT, glucose transporter; LAT, large neutral amino acid transporter; Mal, malate; MCT, monocarboxylate transporter; OA, oxaloacetate; OGC, oxoglutarate carrier; PC, pyruvate carrier; PEP, phosphoenolpyruvate; Pyr, pyruvate; SGLT, sodium–glucose-linked transporter; SNAT, sodium neutral amino acid transporter; 2-OG, 2-oxoglutarate.
Ijms 25 07037 g006

Alanine and Lactate Production by Enterocytes

The outflow from the small intestine by the mesenteric vein is characterized by decreased concentrations of glutamine and increased concentrations of glucose, ammonia, arginine, citrulline, proline, lactate, and alanine when compared with concentration of these substances in mesenteric artery [14,49,66]. The release of alanine and lactate is undoubtedly important for gluconeogenesis in the liver. However, the pathways of alanine and lactate synthesis in enterocytes are unclear.
The studies using L-[14C]glutamine administration have shown that in addition to glucose, glutamine is also a source of pyruvate for alanine and lactate synthesis [64,66]. The glutamine carbons are supposed to appear in pyruvate via phosphoenolpyruvate, which is converted to pyruvate by pyruvate kinase [50]. The ALT and lactate dehydrogenase reactions are driven toward alanine and lactate synthesis, probably due to the low pyruvate carboxylase activity shown in enterocytes of fasted and diabetic rats [64]. LAT2 and LAT4 mediate the efflux of alanine through the basolateral membrane into the blood [24].

5. Predicted Roles of Alanine and Glutamine in Gluconeogenesis under Various Physiological and Pathological Conditions

5.1. High-Protein Diet

A high-protein diet increases aminoacidemia, particularly BCAA, alanine, and glutamine levels, secretion of both insulin and glucagon, and gluconeogenesis and urea synthesis in the liver [44,45,46,69,70,71]. Alanine and glutamine levels increase more than other amino acids because the increased supply of BCAA (due to negligible intestinal and hepatic BAA catabolism) activates their synthesis in muscles and adipose tissue.
Because most of the glutamine obtained from food is utilized in enterocytes, while alanine is synthesized and transported directly to the liver via the portal vein, alanine seems to be a preferred substrate. The increase in alanine was higher than glutamine in the plasma of rats fed a BCAA- or leucine-enriched diet compared to controls fed by a standard diet [72]. Alanine increased from 527 ± 27 to 667 ± 25 and 627 ± 13 µmol/L (19%) in BCAA and leucine group, respectively; glutamine from 713 ± 25 to 825 ± 12 µmol/L (16%) in BCAA group and 808 ± 19 µmol/L (13%) in leucine group. Evaluation of circadian variations in amino acid levels in men demonstrated marked increase in plasma concentration of alanine after each meal, whereas glutamine varied without the influence of food intake [73].
French investigators have demonstrated that a protein-enriched diet stimulates gluconeogenesis in the small intestine and suggest that increased glucose level in the portal vein initiates signals to the hypothalamic nuclei that contribute to the regulation of food intake [14,74]. Induction of the main gluconeogenic genes has also been shown in the kidneys of rats fed a high-protein diet [75].

5.2. High-Fat Diet

Exposure to high-fat diets stimulates gluconeogenesis in the liver [76,77,78,79]. It is assumed that increased production of acetyl-CoA, NADH, and ATP from fatty acid oxidation shifts pyruvate from pyruvate dehydrogenase towards pyruvate carboxylase to form oxaloacetate and decreases fluxes through the CAC and GDH toward 2-OG. Therefore, hepatic gluconeogenesis from alanine is likely activated and glutamine inhibited. The suggestion agrees with data obtained from studies using rat liver perfused by oleate [76]. Furthermore, because high-fat diets contain the necessary amounts of proteins, the supply of alanine to the liver is higher since the majority of glutamine received in food is used by enterocytes to synthesize other amino acids, including alanine.

5.3. Early Starvation

Early starvation refers to the first two days of starvation in which the main role in maintaining glycemia has gluconeogenesis from amino acids evidenced by the increased urea release in urine [6,44,46]. The needs of BCAA as a source of nitrogen for alanine and glutamine synthesis are ensured by a decreased ratio of protein synthesis to proteolysis due to the decline in insulin and increase in glucagon concentrations. Alanine synthesis is preferred due to the increased breakdown of glycogen stores in muscles and subsequent pyruvate supply from glycolysis. The glucose synthesized from alanine in the liver can be used in muscles for alanine synthesis again and close the loop known as the glucose-alanine cycle [6].
As a result of the gradual depletion of muscle glycogen stores and subsequent decrease in glycolysis and pyruvate supply, alanine release from muscles decreases, and glutamine production and its potential use for gluconeogenesis increases. Increased use of glutamine for renal and intestinal gluconeogenesis during early starvation has been confirmed by several studies [7,8,14,15,63].

5.4. Prolonged (Protein-Sparing) Starvation

After 2–3 days of starvation, the body starts to use fatty acids and ketone bodies as the preferential energy fuel, slowing the breakdown of proteins and urea production. BCAA transamination and their use for alanine and glutamine synthesis in muscles decreases due to impaired 2-OG supply from the CAC inhibited by decreased glycolysis and increased NADH and FADH2 supply from fatty acid oxidation. Therefore, plasma BCAA levels temporarily increase, and a marked fall in plasma alanine is observed [56,58,80,81]. A rapid rise in glucose concentration after alanine infusion suggests that the decreased alanine supply from muscles is the main cause of its impaired use for hepatic gluconeogenesis [6].
The shift from glutamine utilization in periportal to its synthesis in perivenous hepatocytes and the simultaneous increase in gluconeogenesis and ammoniagenesis from glutamine in the kidneys compensate for decreased gluconeogenesis from alanine and attenuate the acidotic effect of ketone bodies [58,80]. Cahill showed more than 50 years ago that during prolonged starvation in humans, there is a stoichiometric relation between renal ammoniagenesis and gluconeogenesis, and net renal glucose release contributes approximately to one-half of daily systemic glucose appearance [56].
Unlike short-term starvation, the small intestine’s role appears insignificant due to the reduced glutaminase activity and progressive atrophy of the gut [82,83].

5.5. The Final Stage of Starvation

After 7–8 weeks of starvation, energy stores in the form of glycogen and lipids are exhausted, and amino acids become the only source of energy and a substrate for gluconeogenesis. Evidence of the dominant use of amino acids in the terminal phase of starvation is the increase in the activity of enzymes necessary for amino acid oxidation and increased urea synthesis in the liver and its release by the kidney [5,27,28,56].
Increased proteolysis in muscles is associated with the activation of BCKA dehydrogenase and catabolism of the BCAA, which becomes the primary energy substrate and the source of both nitrogen and carbons for glutamine synthesis. Due to the limited pyruvate supply from glycolysis, alanine synthesis in muscles and its use for gluconeogenesis in the liver should be very low.

5.6. Acidosis

In acidosis, there is increased extraction of glutamine and activation of ammoniagenesis and gluconeogenesis in the kidneys [84]. Rat renal mRNA levels that encode glutaminase and PEPCK increase 6-fold [85]. In vitro studies performed on cortical renal tubules failed to demonstrate increased glucose production from alanine [86].
In acidosis, the glutamine supply to the kidneys is enhanced because of its activated synthesis in muscles and the liver whereas its hepatosplanchnic uptake is decreased [51,53,87,88,89]. In rats with metabolic acidosis, glutamine release by the hindquarters increased from 79 ± 14 to 391 ± 59 nmol/min/100 g, whereas alanine release decreased from 203 ± 12 to 37 ± 13 nmol/min/100 g of body weight [88]. In the liver, the drop in pH inhibits carbamoyl phosphate synthetase in periportal hepatocytes and ammonia detoxification to urea, whereas ammonia detoxification to glutamine increases in perivenous hepatocytes [51,53]. Markedly reduced hepatosplanchnic glutamine uptake and decreased glutaminase activity in the jejunum have been shown in dogs and rats with acidosis [83,89].

5.7. Untreated Diabetes Mellitus of the First Type (T1DM)

In T1DM, the expression of gluconeogenic enzymes is enhanced in all three gluconeogenic organs [14,15,64]. Acidosis resulting from enhanced levels of ketone bodies should increase protein breakdown and glutamine release from muscles and perivenous hepatocytes and its utilization in the kidneys [51,53]. Gluconeogenesis from alanine in the liver is strongly suggested by decreased alanine levels and accelerated hepatic removal of exogenous load of alanine observed in patients with T1DM [90,91,92]. A role in decreased concentrations of alanine in plasma have also impaired pyruvate supply from glycolysis and decreased 2-OG supply for BCAA aminotransferase due to increased fatty acid oxidation in muscles. Therefore, although proteolysis and BCAA oxidation in muscles are increased, decreased alanine and increased BCAA levels are frequent findings in untreated T1DM [92,93].

5.8. Diabetes Mellitus Type 2 (T2DM)

Hyperglucagonemia, insulin resistance, and increased fatty acid oxidation are the main causes of increased gluconeogenesis in T2DM [94,95]. Isotopic techniques have demonstrated that the conversion of both alanine and glutamine to glucose is increased in the liver and kidneys, respectively [59,96,97,98,99]. The importance of alanine demonstrates the abundance of mitochondrial isoform of ALT in the liver of animals and humans with T2DM and that silencing of the enzyme attenuates hyperglycemia [99,100].
Similar to T1DM, plasma BCAA levels increase due to impaired BCAA transamination and alanine and glutamine synthesis in muscles [101]. An alternative source of alanine can be glutaminolysis in the small intestine. A source of both alanine and glutamine can be adipose tissue that produces these amino acids in a postprandial state, and its volume is often enlarged in T2DM.

5.9. Systemic Inflammatory Response (SIR)

The SIR is a non-specific defense response of the body that occurs in severe illnesses, including sepsis, polytrauma, burns, hemorrhage, and heart failure [102,103]. The cause is a complex of neurohumoral changes, primarily increased levels of cytokines, catecholamines, glucagon, and cortisol. Characteristic manifestations include hyperglycemia, increased gluconeogenesis, insulin resistance, and muscle wasting [104,105]. Increased flux of BCKA through BCKA dehydrogenase activated by proinflammatory cytokines and glucocorticoids plays a role in increased BCAA catabolism that becomes, besides a source of the nitrogen for alanine and glutamine synthesis, an energy substrate and a source of the carbons for glutamine synthesis [29,30,106,107,108,109].
Increased losses of urea by urine indicate that most amino acids released from the muscles are utilized in the liver [110]. In rats with sepsis, marked increases in the net rates of hepatic extraction of both glutamine and alanine with concomitant increases in the release of glucose were demonstrated [111]. Hypoalaninaemia and increased removal of intravenous alanine were shown in patients undergoing total hip replacement [92]. Glutamine utilization by various tissues, particularly the immune system, gut, and proximal tubules of the kidneys, often exceeds its synthesis in muscles, and the glutamine level can drop below 50% of its usual concentration. Such a significant decrease in glutamine is accompanied by an increase in mortality, apparently due to insufficient immune system function [30].

5.10. Liver Cirrhosis

Patients with liver cirrhosis have reduced glycogen stores, and their ability to maintain glycemia through hepatic glycogenolysis in a postabsorptive state is limited. Therefore, gluconeogenesis to sustain glycemia is activated much earlier than in a healthy individual [112,113,114,115].
The primary substrate for gluconeogenesis is likely glutamine, whose synthesis is activated by increased ammonia detoxification to glutamine by glutamine synthetase in muscles [116,117,118,119]. Marked increase in glutamate consumption by glutamine synthetase is the main cause of increased flux through BCAA aminotransferase (BCAA + 2-OG → BCKA + Glu), resulting in the decrease in BCAA levels, the drain of 2-OG from the CAC, and impaired mitochondrial function in muscles [120]. The essential role of glutamine in renal gluconeogenesis and glycemia maintenance has been demonstrated by reduced ammoniagenesis in kidneys after overnight glucose infusion in subjects with cirrhosis compared to healthy individuals [121]. The intestine’s role is suggested by observing nearly four times higher intestinal glutaminase activity in cirrhotic patients than in control subjects [122]. Gluconeogenesis from glycerol is not increased in overnight fasted patients with liver cirrhosis [123].

6. Summary and Conclusions

The results of in vitro, animal, and human studies demonstrate that both alanine and glutamine play an essential role in gluconeogenesis in various physiological and pathological conditions. Alanine is more important in gluconeogenesis in the liver; glutamine is the primary precursor for gluconeogenesis in the kidneys and small intestine. Because a significant portion of alanine carbons, but not carbons of glutamine, originate from glucose catabolism, glutamine should be recognized as a better substrate for gluconeogenesis than alanine. Furthermore, glutamine’s appearance rate in circulation is higher than that of alanine, and ATP can be produced during glutamine catabolism due to NADH and FADH2 release from the CAC during 2-OG conversion to oxaloacetate. On the other hand, alanine conversion to oxaloacetate by pyruvate carboxylase is an ATP-consuming reaction. It can be assumed that the differences in energy requirements for glutamine and alanine conversion to oxaloacetate can influence their entry in gluconeogenesis, especially in states with energy deficits such as cachexia and long-term starvation.
Alanine supply and conversion to oxaloacetate are favored in early starvation and after exposure to high-fat or high-protein diets. Enhanced use of alanine for gluconeogenesis has been reported also in diabetes. In contrast, glutamine use in gluconeogenesis, particularly in kidneys, is stimulated during prolonged starvation, acidosis, illnesses associated with systemic inflammatory response, and liver cirrhosis.
The data discussed in the article suggest meaningful relationships among muscles, liver, kidneys, and small intestine that ensure the supply of alanine and glutamine to individual gluconeogenic organs (Figure 7). For instance, under acidotic conditions, glutamine utilization for gluconeogenesis and urea synthesis in periportal hepatocytes is inhibited, whereas its synthesis in perivenous hepatocytes and release into the bloodstream is stimulated. Subsequently, glutamine is used by kidneys for glucose and ammonia synthesis to maintain glycemia and acid-base balance, respectively.
In conclusion, a better understanding of pathways in which alanine and glutamine, and other gluconeogenic substrates are involved in gluconeogenesis in individual glucogenic organs is required for therapy of disorders of glucose homeostasis.

Funding

Charles University, the Cooperatio Program, research area METD supported this work.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The author declares no conflicts of interest.

References

  1. Wu, X.; Chen, S. Advances in natural small molecules on pretranslational regulation of gluconeogenesis. Drug Dev. Res. 2023, 84, 613–628. [Google Scholar] [CrossRef] [PubMed]
  2. Oh, K.J.; Han, H.S.; Kim, M.J.; Koo, S.H. Transcriptional regulators of hepatic gluconeogenesis. Arch. Pharm. Res. 2013, 36, 189–200. [Google Scholar] [CrossRef]
  3. Sahoo, B.; Srivastava, M.; Katiyar, A.; Ecelbarger, C.; Tiwari, S. Liver or kidney: Who has the oar in the gluconeogenesis boat and when? World J. Diabetes 2023, 14, 1049–1056. [Google Scholar] [CrossRef] [PubMed]
  4. Mutel, E.; Gautier-Stein, A.; Abdul-Wahed, A.; Amigó-Correig, M.; Zitoun, C.; Stefanutti, A.; Houberdon, I.; Tourette, J.A.; Mithieux, G.; Rajas, F. Control of blood glucose in the absence of hepatic glucose production during prolonged fasting in mice: Induction of renal and intestinal gluconeogenesis by glucagon. Diabetes 2011, 60, 3121–3131. [Google Scholar] [CrossRef] [PubMed]
  5. Felig, P.; Owen, O.E.; Wahren, J.; Cahill, G.F., Jr. Amino acid metabolism during prolonged starvation. J. Clin. Investig. 1969, 48, 584–594. [Google Scholar] [CrossRef] [PubMed]
  6. Felig, P. The glucose-alanine cycle. Metabolism 1973, 22, 179–207. [Google Scholar] [CrossRef] [PubMed]
  7. Gerich, J.E.; Meyer, C.; Woerle, H.J.; Stumvoll, M. Renal gluconeogenesis: Its importance in human glucose homeostasis. Diabetes Care 2001, 24, 382–391. [Google Scholar] [CrossRef]
  8. Stumvoll, M.; Meyer, C.; Kreider, M.; Perriello, G.; Gerich, J. Effects of glucagon on renal and hepatic glutamine gluconeogenesis in normal postabsorptive humans. Metabolism 1998, 47, 1227–1232. [Google Scholar] [CrossRef] [PubMed]
  9. Mitrakou, A. Kidney: Its impact on glucose homeostasis and hormonal regulation. Diabetes Res. Clin. Pract. 2011, 93, S66–S72. [Google Scholar] [CrossRef] [PubMed]
  10. Legouis, D.; Faivre, A.; Cippà, P.E.; de Seigneux, S. Renal gluconeogenesis: An underestimated role of the kidney in systemic glucose metabolism. Nephrol. Dial. Transplant. 2022, 37, 1417–1425. [Google Scholar] [CrossRef]
  11. Perriello, G.; Jorde, R.; Nurjhan, N.; Stumvoll, M.; Dailey, G.; Jenssen, T.; Bier, D.M.; Gerich, J.E. Estimation of glucose-alanine-lactate-glutamine cycles in postabsorptive humans: Role of skeletal muscle. Am. J. Physiol. 1995, 269, E443–E450. [Google Scholar] [CrossRef]
  12. Waterhouse, C.; Keilson, J. The contribution of glucose to alanine metabolism in man. J. Lab. Clin. Med. 1978, 92, 803–812. [Google Scholar] [PubMed]
  13. Nurjhan, N.; Bucci, A.; Perriello, G.; Stumvoll, M.; Dailey, G.; Bier, D.M.; Toft, I.; Jenssen, T.G.; Gerich, J.E. Glutamine: A major gluconeogenic precursor and vehicle for interorgan carbon transport in man. J. Clin. Investig. 1995, 95, 272–277. [Google Scholar] [CrossRef] [PubMed]
  14. Mithieux, G.; Gautier-Stein, A. Intestinal glucose metabolism revisited. Diabetes Res. Clin. Pract. 2014, 105, 295–301. [Google Scholar] [CrossRef] [PubMed]
  15. Rajas, F.; Bruni, N.; Montano, S.; Zitoun, C.; Mithieux, G. The glucose-6 phosphatase gene is expressed in human and rat small intestine: Regulation of expression in fasted and diabetic rats. Gastroenterology 1999, 117, 132–139. [Google Scholar] [CrossRef] [PubMed]
  16. Darmaun, D.; Matthews, D.E.; Bier, D.M. Physiological hypercortisolemia increases proteolysis, glutamine, and alanine production. Am. J. Physiol. 1988, 255, E366–E373. [Google Scholar] [CrossRef] [PubMed]
  17. Harper, A.E.; Miller, R.H.; Block, K.P. Branched-chain amino acid metabolism. Annu. Rev. Nutr. 1984, 4, 409–454. [Google Scholar] [CrossRef] [PubMed]
  18. Skeie, B.; Kvetan, V.; Gil, K.M.; Rothkopf, M.M.; Newsholme, E.A.; Askanazi, J. Branch-chain amino acids: Their metabolism and clinical utility. Crit. Care Med. 1990, 18, 549–571. [Google Scholar] [CrossRef] [PubMed]
  19. Haymond, M.W.; Miles, J.M. Branched chain amino acids as a major source of alanine nitrogen in man. Diabetes 1982, 31, 86–89. [Google Scholar] [CrossRef]
  20. Galim, E.B.; Hruska, K.; Bier, D.M.; Matthews, D.E.; Haymond, M.W. Branched-chain amino acid nitrogen transfer to alanine in vivo in dogs. Direct isotopic determination with [15N]leucine. J. Clin. Investig. 1980, 66, 1295–1304. [Google Scholar] [CrossRef]
  21. Vozza, A.; Parisi, G.; De Leonardis, F.; Lasorsa, F.M.; Castegna, A.; Amorese, D.; Marmo, R.; Calcagnile, V.M.; Palmieri, L.; Ricquier, D.; et al. UCP2 transports C4 metabolites out of mitochondria, regulating glucose and glutamine oxidation. Proc. Natl. Acad. Sci. USA 2014, 111, 960–965. [Google Scholar] [CrossRef]
  22. Monné, M.; Vozza, A.; Lasorsa, F.M.; Porcelli, V.; Palmieri, F. Mitochondrial carriers for aspartate, glutamate and other amino acids: A review. Int. J. Mol. Sci. 2019, 20, 4456. [Google Scholar] [CrossRef] [PubMed]
  23. Tornheim, K.; Lowenstein, J.M. The purine nucleotide cycle. The production of ammonia from aspartate by extracts of rat skeletal muscle. J. Biol. Chem. 1972, 247, 162–169. [Google Scholar] [CrossRef]
  24. Bröer, S. Amino acid transporters as modulators of glucose homeostasis. Trends Endocrinol. Metab. 2022, 33, 120–135. [Google Scholar] [CrossRef] [PubMed]
  25. Chang, T.W.; Goldberg, A.L. The metabolic fates of amino acids and the formation of glutamine in skeletal muscle. J. Biol. Chem. 1978, 253, 3685–3693. [Google Scholar] [CrossRef]
  26. Wagenmakers, A.J.; Salden, H.J.; Veerkamp, J.H. The metabolic fate of branched-chain amino acids and 2-oxo acids in rat muscle homogenates and diaphragms. Int. J. Biochem. 1985, 17, 957–965. [Google Scholar] [CrossRef]
  27. Holecek, M. Leucine metabolism in fasted and tumor necrosis factor-treated rats. Clin. Nutr. 1996, 15, 91–93. [Google Scholar] [CrossRef]
  28. Holecek, M. Effect of starvation on branched-chain alpha-keto acid dehydrogenase activity in rat heart and skeletal muscle. Physiol. Res. 2001, 50, 19–24. [Google Scholar] [CrossRef]
  29. Nawabi, M.D.; Block, K.P.; Chakrabarti, M.C.; Buse, M.G. Administration of endotoxin, tumor necrosis factor, or interleukin 1 to rats activates skeletal muscle branched-chain alpha-keto acid dehydrogenase. J. Clin. Investig. 1990, 85, 256–263. [Google Scholar] [CrossRef] [PubMed]
  30. Wischmeyer, P.E. Glutamine: Role in critical illness and ongoing clinical trials. Curr. Opin. Gastroenterol. 2008, 24, 190–197. [Google Scholar] [CrossRef]
  31. Frayn, K.N.; Khan, K.; Coppack, S.W.; Elia, M. Amino acid metabolism in human subcutaneous adipose tissue in vivo. Clin. Sci. (Lond.) 1991, 80, 471–474. [Google Scholar] [CrossRef] [PubMed]
  32. Tischler, M.E.; Goldberg, A.L. Leucine degradation and release of glutamine and alanine by adipose tissue. J. Biol. Chem. 1980, 255, 8074–8081. [Google Scholar] [CrossRef] [PubMed]
  33. Plumley, D.A.; Souba, W.W.; Hautamaki, R.D.; Martin, T.D.; Flynn, T.C.; Rout, W.R.; Copeland, E.M. Accelerated lung amino acid release in hyperdynamic septic surgical patients. Arch. Surg. 1990, 125, 57–61. [Google Scholar] [CrossRef] [PubMed]
  34. Conti, F.; Melone, M. The glutamine commute: Lost in the tube? Neurochem. Int. 2006, 48, 459–464. [Google Scholar] [CrossRef] [PubMed]
  35. Yang, R.Z.; Park, S.; Reagan, W.J.; Goldstein, R.; Zhong, S.; Lawton, M.; Rajamohan, F.; Qian, K.; Liu, L.; Gong, D.W. Alanine aminotransferase isoenzymes: Molecular cloning and quantitative analysis of tissue expression in rats and serum elevation in liver toxicity. Hepatology 2009, 49, 598–607. [Google Scholar] [CrossRef] [PubMed]
  36. Jitrapakdee, S.; Wallace, J.C. Structure, function and regulation of pyruvate carboxylase. Biochem. J. 1999, 340, 1–16. [Google Scholar] [CrossRef] [PubMed]
  37. Curthoys, N.P.; Watford, M. Regulation of glutaminase activity and glutamine metabolism. Annu. Rev. Nutr. 1995, 15, 133–159. [Google Scholar] [CrossRef] [PubMed]
  38. Treberg, J.R.; Banh, S.; Pandey, U.; Weihrauch, D. Intertissue differences for the role of glutamate dehydrogenase in metabolism. Neurochem. Res. 2014, 39, 516–526. [Google Scholar] [CrossRef] [PubMed]
  39. Spanaki, C.; Plaitakis, A. The role of glutamate dehydrogenase in mammalian ammonia metabolism. Neurotox. Res. 2012, 21, 117–127. [Google Scholar] [CrossRef]
  40. Amoedo, N.D.; Punzi, G.; Obre, E.; Lacombe, D.; De Grassi, A.; Pierri, C.L.; Rossignol, R. AGC1/2, the mitochondrial aspartate-glutamate carriers. Biochim. Biophys. Acta 2016, 1863, 2394–2412. [Google Scholar] [CrossRef]
  41. Holeček, M. Roles of malate and aspartate in gluconeogenesis in various physiological and pathological states. Metabolism 2023, 145, 155614. [Google Scholar] [CrossRef] [PubMed]
  42. Owen, O.E.; Reichle, F.A.; Mozzoli, M.A.; Kreulen, T.; Patel, M.S.; Elfenbein, I.B.; Golsorkhi, M.; Chang, K.H.; Rao, N.S.; Sue, H.S.; et al. Hepatic, gut, and renal substrate flux rates in patients with hepatic cirrhosis. J. Clin. Investig. 1981, 68, 240–252. [Google Scholar] [CrossRef] [PubMed]
  43. van de Poll, M.C.; Ligthart-Melis, G.C.; Boelens, P.G.; Deutz, N.E.; van Leeuwen, P.A.; Dejong, C.H. Intestinal and hepatic metabolism of glutamine and citrulline in humans. J. Physiol. 2007, 581, 819–827. [Google Scholar] [CrossRef] [PubMed]
  44. Jungas, R.L.; Halperin, M.L.; Brosnan, J.T. Quantitative analysis of amino acid oxidation and related gluconeogenesis in humans. Physiol. Rev. 1992, 72, 419–448. [Google Scholar] [CrossRef] [PubMed]
  45. Schutz, Y. Protein turnover, ureagenesis and gluconeogenesis. Int. J. Vitam. Nutr. Res. 2011, 81, 101–107. [Google Scholar] [CrossRef]
  46. Veldhorst, M.A.; Westerterp-Plantenga, M.S.; Westerterp, K.R. Gluconeogenesis and energy expenditure after a high-protein, carbohydrate-free diet. Am. J. Clin. Nutr. 2009, 90, 519–526. [Google Scholar] [CrossRef]
  47. Cooper, A.J.; Nieves, E.; Rosenspire, K.C.; Filc-DeRicco, S.; Gelbard, A.S.; Brusilow, S.W. Short-term metabolic fate of 13N-labeled glutamate, alanine, and glutamine(amide) in rat liver. J. Biol. Chem. 1988, 263, 12268–12273. [Google Scholar] [CrossRef]
  48. Neis, E.P.; Sabrkhany, S.; Hundscheid, I.; Schellekens, D.; Lenaerts, K.; Olde Damink, S.W.; Blaak, E.E.; Dejong, C.H.; Rensen, S.S. Human splanchnic amino-acid metabolism. Amino Acids 2017, 49, 161–172. [Google Scholar] [CrossRef] [PubMed]
  49. Windmueller, H.G.; Spaeth, A.E. Uptake and metabolism of plasma glutamine by the small intestine. J. Biol. Chem. 1974, 249, 5070–5079. [Google Scholar] [CrossRef]
  50. Hanson, P.J.; Parsons, D.S. The interrelationship between glutamine and alanine in the intestine. Biochem. Soc. Trans. 1980, 8, 506–509. [Google Scholar] [CrossRef]
  51. Häussinger, D.; Stoll, B.; Stehle, T.; Gerok, W. Hepatocyte heterogeneity in glutamate metabolism and bidirectional transport in perfused rat liver. Eur. J. Biochem. 1989, 185, 189–195. [Google Scholar] [CrossRef] [PubMed]
  52. Brosnan, M.E.; Brosnan, J.T. Hepatic glutamate metabolism: A tale of 2 hepatocytes. Am. J. Clin. Nutr. 2009, 90, 857S–861S. [Google Scholar] [CrossRef] [PubMed]
  53. Nissim, I. Newer aspects of glutamine/glutamate metabolism: The role of acute pH changes. Am. J. Physiol. 1999, 277, F493–F497. [Google Scholar] [CrossRef] [PubMed]
  54. McGivan, J.D.; Bungard, C.I. The transport of glutamine into mammalian cells. Front. Biosci. 2007, 12, 874–882. [Google Scholar] [CrossRef] [PubMed]
  55. Triplitt, C.L. Understanding the kidneys’ role in blood glucose regulation. Am. J. Manag. Care 2012, 18, S11–S16. [Google Scholar] [PubMed]
  56. Cahill, G.F., Jr. Starvation in man. N. Engl. J. Med. 1970, 282, 668–675. [Google Scholar] [CrossRef]
  57. Cersosimo, E.; Garlick, P.; Ferretti, J. Insulin regulation of renal glucose metabolism in humans. Am. J. Physiol. 1999, 276, E78–E84. [Google Scholar] [CrossRef]
  58. Miller, B.M.; Cersosimo, E.; McRae, J.; Williams, P.E.; Lacy, W.W.; Abumrad, N.N. Interorgan relationships of alanine and glutamine during fasting in the conscious dog. J. Surg. Res. 1983, 35, 310–318. [Google Scholar] [CrossRef] [PubMed]
  59. Meyer, C.; Stumvoll, M.; Nadkarni, V.; Dostou, J.; Mitrakou, A.; Gerich, J. Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus. J. Clin. Investig. 1998, 102, 619–624. [Google Scholar] [CrossRef]
  60. Vinay, P.; Lemieux, G.; Gougoux, A.; Halperin, M. Regulation of glutamine metabolism in dog kidney in vivo. Kidney Int. 1986, 29, 68–79. [Google Scholar] [CrossRef]
  61. Verrey, F.; Singer, D.; Ramadan, T.; Vuille-dit-Bille, R.N.; Mariotta, L.; Camargo, S.M. Kidney amino acid transport. Pflugers Arch. 2009, 458, 53–60. [Google Scholar] [CrossRef] [PubMed]
  62. Pitts, R.F.; Stone, W.J. Renal metabolism of alanine. J. Clin. Investig. 1967, 46, 530–538. [Google Scholar] [CrossRef] [PubMed]
  63. Anderson, J.W. Glucose metabolism in jejunal mucosa of fed, fasted, and streptozotocin-diabetic rats. Am. J. Physiol. 1974, 226, 226–229. [Google Scholar] [CrossRef] [PubMed]
  64. Croset, M.; Rajas, F.; Zitoun, C.; Hurt, J.M.; Montano, S.; Mithieux, G. Rat small intestine is an insulin-sensitive gluconeogenic organ. Diabetes 2001, 50, 740–746. [Google Scholar] [CrossRef] [PubMed]
  65. James, L.A.; Lunn, P.G.; Middleton, S.; Elia, M. Distribution of glutaminase and glutamine synthetase activities in the human gastrointestinal tract. Clin. Sci. 1998, 94, 313–319. [Google Scholar] [CrossRef] [PubMed]
  66. Watford, M. Glutamine metabolism in rat small intestine: Synthesis of three-carbon products in isolated enterocytes. Biochim. Biophys. Acta 1994, 1200, 73–78. [Google Scholar] [CrossRef] [PubMed]
  67. Kimura, R.E. Glutamine oxidation by developing rat small intestine. Pediatr. Res. 1987, 21, 214–217. [Google Scholar] [CrossRef] [PubMed]
  68. Johnson, A.W.; Berrington, J.M.; Walker, I.; Manning, A.; Losowsky, M.S. Measurement of the transfer of the nitrogen moiety of intestinal lumen glutamic acid in man after oral ingestion of l-[15N]glutamic acid. Clin. Sci. 1988, 75, 499–502. [Google Scholar] [CrossRef] [PubMed]
  69. LeBlanc, J.; Soucy, J.; Nadeau, A. Early insulin and glucagon responses to different food items. Horm. Metab. Res. 1996, 28, 276–279. [Google Scholar] [CrossRef]
  70. Moon, J.; Koh, G. Clinical evidence and mechanisms of high-protein diet-induced weight loss. J. Obes. Metab. Syndr. 2020, 29, 166–173. [Google Scholar] [CrossRef]
  71. Linn, T.; Santosa, B.; Grönemeyer, D.; Aygen, S.; Scholz, N.; Busch, M.; Bretzel, R.G. Effect of long-term dietary protein intake on glucose metabolism in humans. Diabetologia 2000, 43, 1257–1265. [Google Scholar] [CrossRef] [PubMed]
  72. Holecek, M.; Siman, P.; Vodenicarovova, M.; Kandar, R. Alterations in protein and amino acid metabolism in rats fed a branched-chain amino acid- or leucine-enriched diet during postprandial and postabsorptive states. Nutr. Metab. 2016, 13, 12. [Google Scholar] [CrossRef] [PubMed]
  73. Tsai, P.J.; Huang, P.C. Circadian variations in plasma and erythrocyte concentrations of glutamate, glutamine, and alanine in men on a diet without and with added monosodium glutamate. Metabolism 1999, 48, 1455–1460. [Google Scholar] [CrossRef] [PubMed]
  74. Gautier-Stein, A.; Rajas, F.; Mithieux, G. Intestinal gluconeogenesis and protein diet: Future directions. Proc. Nutr. Soc. 2021, 80, 118–125. [Google Scholar] [CrossRef] [PubMed]
  75. Pillot, B.; Soty, M.; Gautier-Stein, A.; Zitoun, C.; Mithieux, G. Protein feeding promotes redistribution of endogenous glucose production to the kidney and potentiates its suppression by insulin. Endocrinology 2009, 150, 616–624. [Google Scholar] [CrossRef] [PubMed]
  76. Martín-Requero, A.; Ciprés, G.; Rivas, T.; Ayuso, M.S.; Parrilla, R. Reciprocal changes in gluconeogenesis and ureagenesis induced by fatty acid oxidation. Metabolism 1993, 42, 1573–1582. [Google Scholar] [CrossRef]
  77. Sarabhai, T.; Kahl, S.; Szendroedi, J.; Markgraf, D.F.; Zaharia, O.P.; Barosa, C.; Herder, C.; Wickrath, F.; Bobrov, P.; Hwang, J.H.; et al. Monounsaturated fat rapidly induces hepatic gluconeogenesis and whole-body insulin resistance. JCI Insight 2020, 5, e134520. [Google Scholar] [CrossRef] [PubMed]
  78. Hernández, E.Á.; Kahl, S.; Seelig, A.; Begovatz, P.; Irmler, M.; Kupriyanova, Y.; Nowotny, B.; Nowotny, P.; Herder, C.; Barosa, C.; et al. Acute dietary fat intake initiates alterations in energy metabolism and insulin resistance. J. Clin. Investig. 2017, 127, 695–708. [Google Scholar] [CrossRef]
  79. Cairns, R.; Fischer, A.W.; Blanco-Munoz, P.; Alvarez-Guaita, A.; Meneses-Salas, E.; Egert, A.; Buechler, C.; Hoy, A.J.; Heeren, J.; Enrich, C.; et al. Altered hepatic glucose homeostasis in AnxA6-KO mice fed a high-fat diet. PLoS ONE 2018, 13, e0201310. [Google Scholar] [CrossRef]
  80. Lopez, H.W.; Moundras, C.; Morand, C.; Demigné, C.; Rémésy, C. Opposite fluxes of glutamine and alanine in the splanchnic area are an efficient mechanism for nitrogen sparing in rats. J. Nutr. 1998, 128, 1487–1494. [Google Scholar] [CrossRef]
  81. Holeček, M. Why Are Branched-Chain Amino Acids Increased in Starvation and Diabetes? Nutrients 2020, 12, 3087. [Google Scholar] [CrossRef] [PubMed]
  82. Kong, S.E.; Hall, J.C.; Cooper, D.; McCauley, R.D. Starvation alters the activity and mRNA level of glutaminase and glutamine synthetase in the rat intestine. J. Nutr. Biochem. 2000, 11, 393–400. [Google Scholar] [CrossRef] [PubMed]
  83. McFarlane Anderson, N.; Bennett, F.I.; Alleyne, G.A. Ammonia production by the small intestine of the rat. Biochim. Biophys. Acta 1976, 437, 238–243. [Google Scholar] [CrossRef] [PubMed]
  84. Alleyne, G.A.; Lupianez, J.A.; McFarlane-Anderson, N.; Hortelano, P.; Benjamin, J.; Barnswell, J.; Scott, B. Glutamine metabolism in metabolic acidosis. Ciba Found. Symp. 1982, 87, 101–119. [Google Scholar] [PubMed]
  85. Hwang, J.J.; Curthoys, N.P. Effect of acute alterations in acid-base balance on rat renal glutaminase and phosphoenolpyruvate carboxykinase gene expression. J. Biol. Chem. 1991, 266, 9392–9396. [Google Scholar] [CrossRef] [PubMed]
  86. Lemieux, G.; Berkofsky, J.; Lemieux, C.; Quenneville, A.; Marsolais, M. Real importance of alanine in renal metabolism: In vitro studies in rat and dog. Am. J. Physiol. 1988, 255, R42–R45. [Google Scholar] [CrossRef] [PubMed]
  87. Schröck, H.; Goldstein, L. Interorgan relationships for glutamine metabolism in normal and acidotic rats. Am. J. Physiol. 1981, 240, E519–E525. [Google Scholar] [CrossRef] [PubMed]
  88. Welbourne, T.C. Effect of metabolic acidosis on hindquarter glutamine and alanine release. Metabolism 1986, 35, 614–618. [Google Scholar] [CrossRef] [PubMed]
  89. Fine, A. Effects of acute metabolic acidosis on renal, gut, liver, and muscle metabolism of glutamine and ammonia in the dog. Kidney Int. 1982, 21, 439–444. [Google Scholar] [CrossRef]
  90. Almdal, T.P.; Jensen, T.; Vilstrup, H. Increased hepatic efficacy of urea synthesis from alanine in insulin-dependent diabetes mellitus. Eur. J. Clin. Investig. 1990, 20, 29–34. [Google Scholar] [CrossRef]
  91. Wahren, J.; Felig, P.; Cerasi, E.; Luft, R. Splanchnic and peripheral glucose and amino acid metabolism in diabetes mellitus. J. Clin. Investig. 1972, 51, 1870–1878. [Google Scholar] [CrossRef] [PubMed]
  92. Elia, M.; Ilic, V.; Bacon, S.; Williamson, D.H.; Smith, R. Relationship between the basal blood alanine concentration and the removal of an alanine load in various clinical states in man. Clin. Sci. 1980, 58, 301–309. [Google Scholar] [CrossRef] [PubMed]
  93. Holeček, M.; Vodeničarovová, M.; Fingrová, R. Dual effects of beta-hydroxy-beta-methylbutyrate (HMB) on amino acid, energy, and protein metabolism in the liver and muscles of rats with streptozotocin-induced type 1 diabetes. Biomolecules 2020, 10, 1475. [Google Scholar] [CrossRef] [PubMed]
  94. Shah, A.; Wondisford, F.E. Gluconeogenesis flux in metabolic disease. Annu. Rev. Nutr. 2023, 43, 153–177. [Google Scholar] [CrossRef] [PubMed]
  95. Sharma, R.; Tiwari, S. Renal gluconeogenesis in insulin resistance: A culprit for hyperglycemia in diabetes. World J. Diabetes 2021, 12, 556–568. [Google Scholar] [CrossRef] [PubMed]
  96. Stumvoll, M.; Perriello, G.; Nurjhan, N.; Bucci, A.; Welle, S.; Jansson, P.A.; Dailey, G.; Bier, D.; Jenssen, T.; Gerich, J. Glutamine and alanine metabolism in NIDDM. Diabetes 1996, 45, 863–868. [Google Scholar] [CrossRef] [PubMed]
  97. Consoli, A.; Nurjhan, N.; Reilly, J.J.; Bier, D.M.; Gerich, J.E. Mechanism of increased gluconeogenesis in noninsulin-dependent diabetes mellitus. Role of alterations in systemic, hepatic, and muscle lactate and alanine metabolism. J. Clin. Investig. 1990, 86, 2038–2045. [Google Scholar] [CrossRef] [PubMed]
  98. Qian, K.; Zhong, S.; Xie, K.; Yu, D.; Yang, R.; Gong, D.W. Hepatic ALT isoenzymes are elevated in gluconeogenic conditions including diabetes and suppressed by insulin at the protein level. Diabetes Metab. Res. Rev. 2015, 31, 562–571. [Google Scholar] [CrossRef] [PubMed]
  99. Okun, J.G.; Rusu, P.M.; Chan, A.Y.; Wu, Y.; Yap, Y.W.; Sharkie, T.; Schumacher, J.; Schmidt, K.V.; Roberts-Thomson, K.M.; Russell, R.D.; et al. Liver alanine catabolism promotes skeletal muscle atrophy and hyperglycaemia in type 2 diabetes. Nat. Metab. 2021, 3, 394–409. [Google Scholar] [CrossRef]
  100. Martino, M.R.; Gutiérrez-Aguilar, M.; Yiew, N.K.H.; Lutkewitte, A.J.; Singer, J.M.; McCommis, K.S.; Ferguson, D.; Liss, K.H.H.; Yoshino, J.; Renkemeyer, M.K.; et al. Silencing alanine transaminase 2 in diabetic liver attenuates hyperglycemia by reducing gluconeogenesis from amino acids. Cell Rep. 2022, 39, 110733. [Google Scholar] [CrossRef]
  101. Holeček, M. The role of skeletal muscle in the pathogenesis of altered concentrations of branched-chain amino acids (valine, leucine, and isoleucine) in liver cirrhosis, diabetes, and other diseases. Physiol. Res. 2021, 70, 293–305. [Google Scholar] [CrossRef] [PubMed]
  102. Balk, R.A. Systemic inflammatory response syndrome (SIRS): Where did it come from and is it still relevant today? Virulence 2014, 5, 20–26. [Google Scholar] [CrossRef] [PubMed]
  103. Davies, M.G.; Hagen, P.O. Systemic inflammatory response syndrome. Br. J. Surg. 1997, 84, 920–935. [Google Scholar] [CrossRef] [PubMed]
  104. Al-Yousif, N.; Rawal, S.; Jurczak, M.; Mahmud, H.; Shah, F.A. Endogenous glucose production in critical illness. Nutr. Clin. Pract. 2021, 36, 344–359. [Google Scholar] [CrossRef] [PubMed]
  105. Mizock, B.A. Alterations in carbohydrate metabolism during stress: A review of the literature. Am. J. Med. 1995, 98, 75–84. [Google Scholar] [CrossRef] [PubMed]
  106. Holecek, M.; Sprongl, L.; Skopec, F.; Andrýs, C.; Pecka, M. Leucine metabolism in TNF-alpha- and endotoxin-treated rats: Contribution of hepatic tissue. Am. J. Physiol. 1997, 273, E1052–E1058. [Google Scholar] [PubMed]
  107. Vesali, R.F.; Klaude, M.; Rooyackers, O.; Wernerman, J. Amino acid metabolism in leg muscle after an endotoxin injection in healthy volunteers. Am. J. Physiol. 2005, 288, E360–E364. [Google Scholar] [CrossRef] [PubMed]
  108. Karinch, A.M.; Pan, M.; Lin, C.M.; Strange, R.; Souba, W.W. Glutamine metabolism in sepsis and infection. J. Nutr. 2001, 131, 2535S–2538S. [Google Scholar] [CrossRef] [PubMed]
  109. Muthny, T.; Kovarik, M.; Sispera, L.; Tilser, I.; Holecek, M. Protein metabolism in slow- and fast-twitch skeletal muscle during turpentine-induced inflammation. Int. J. Exp. Pathol. 2008, 89, 64–71. [Google Scholar] [CrossRef]
  110. Meguid, M.M.; Brennan, M.F.; Aoki, T.T.; Muller, W.A.; Ball, M.R.; Moore, F.D. Hormone-substrate interrelationships following trauma. Arch. Surg. 1974, 109, 776–783. [Google Scholar] [CrossRef]
  111. Salleh, M.; Ardawi, M. Hepatic glutamine metabolism in the septic rat. Clin. Sci. 1992, 82, 709–716. [Google Scholar] [CrossRef] [PubMed]
  112. Bugianesi, E.; Kalhan, S.; Burkett, E.; Marchesini, G.; McCullough, A. Quantification of gluconeogenesis in cirrhosis: Response to glucagon. Gastroenterology 1998, 115, 1530–1540. [Google Scholar] [CrossRef]
  113. Petersen, K.F.; Krssak, M.; Navarro, V.; Chandramouli, V.; Hundal, R.; Schumann, W.C.; Landau, B.R.; Shulman, G.I. Contributions of net hepatic glycogenolysis and gluconeogenesis to glucose production in cirrhosis. Am. J. Physiol. 1999, 276, E529–E535. [Google Scholar] [CrossRef] [PubMed]
  114. Perdigoto, R.; Furtado, A.L.; Porto, A.; Rodrigues, T.B.; Geraldes, C.F.; Jones, J.G. Sources of glucose production in cirrhosis by 2H2O ingestion and 2H NMR analysis of plasma glucose. Biochim. Biophys. Acta 2003, 1637, 156–163. [Google Scholar] [CrossRef] [PubMed]
  115. Joseph, S.E.; Heaton, N.; Potter, D.; Pernet, A.; Umpleby, M.A.; Amiel, S.A. Renal glucose production compensates for the liver during the anhepatic phase of liver transplantation. Diabetes 2000, 49, 450–456. [Google Scholar] [CrossRef] [PubMed]
  116. Holecek, M.; Sprongl, L.; Tichý, M. Effect of hyperammonemia on leucine and protein metabolism in rats. Metabolism 2000, 49, 1330–1334. [Google Scholar] [CrossRef] [PubMed]
  117. Holecek, M.; Kandar, R.; Sispera, L.; Kovarik, M. Acute hyperammonemia activates branched-chain amino acid catabolism and decreases their extracellular concentrations: Different sensitivity of red and white muscle. Amino Acids 2011, 40, 575–584. [Google Scholar] [CrossRef] [PubMed]
  118. Rodney, S.; Boneh, A. Amino acid profiles in patients with urea cycle disorders at admission to hospital due to metabolic decompensation. JIMD Rep. 2013, 9, 97–104. [Google Scholar] [PubMed]
  119. Olde Damink, S.W.; Jalan, R.; Redhead, D.N.; Hayes, P.C.; Deutz, N.E.; Soeters, P.B. Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS. Hepatology 2002, 36, 1163–1171. [Google Scholar] [CrossRef]
  120. Holeček, M.; Vodeničarovová, M. Muscle wasting and branched-chain amino acid, alpha-ketoglutarate, and ATP depletion in a rat model of liver cirrhosis. Int. J. Exp. Pathol. 2018, 99, 274–281. [Google Scholar] [CrossRef]
  121. Mpabanzi, L.; Deutz, N.; Hayes, P.C.; Dejong, C.H.; Olde Damink, S.W.; Jalan, R. Overnight glucose infusion suppresses renal ammoniagenesis and reduces hyperammonaemia induced by a simulated bleed in cirrhotic patients. Aliment. Pharmacol. Ther. 2012, 35, 921–928. [Google Scholar] [CrossRef] [PubMed]
  122. Romero-Gómez, M.; Ramos-Guerrero, R.; Grande, L.; de Terán, L.C.; Corpas, R.; Camacho, I.; Bautista, J.D. Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy. J. Hepatol. 2004, 41, 49–54. [Google Scholar] [CrossRef] [PubMed]
  123. Kruszynska, Y.T.; McIntyre, N. Gluconeogenesis from glycerol is not increased in overnight fasted cirrhotic patients. Clin. Sci. 1994, 87, 11P–12P. [Google Scholar] [CrossRef]
Ijms 25 07037 g001
Figure 1. BCAAs as a substrate for alanine and glutamine synthesis in muscles. 1, BCAA aminotransferase; 2, AST (mitochondrial); 3, AST (cytosolic); 4, ALT; 5, glutamine synthetase; 6, BCKA dehydrogenase; 7, enzymes converting BCA-CoAs into acetyl-CoA, acetoacetate, or succinyl-CoA; 8, malate dehydrogenase (mitochondrial); 9, β-oxidation; 10, citrate synthase; 11, adenylosuccinate synthetase; 12, adenylate deaminase. Abbreviations: AGC1, aspartate–glutamate carrier; ASCT, alanine, serine, cysteine, and threonine carrier; BAT, BCAA transporter (SLC25A4); BCAA, branched-chain amino acids; BCA-CoA, branched-chain acyl-CoA; BCKA, branched-chain keto acids; CAC, citric acid cycle; CS, carnitine system; EAAT, excitatory amino acid transporters; GLUT, glucose transporter; LAT1, large neutral amino acid transporter 1; MCT, monocarboxylate transporter; OA, oxaloacetate; OGC, 2-oxoglutarate carrier; PC, pyruvate carrier; PNC, purine-nucleotide cycle; Pyr, pyruvate; SNAT, sodium neutral amino acid transporter; 2-OG, 2-oxoglutarate.
Figure 1. BCAAs as a substrate for alanine and glutamine synthesis in muscles. 1, BCAA aminotransferase; 2, AST (mitochondrial); 3, AST (cytosolic); 4, ALT; 5, glutamine synthetase; 6, BCKA dehydrogenase; 7, enzymes converting BCA-CoAs into acetyl-CoA, acetoacetate, or succinyl-CoA; 8, malate dehydrogenase (mitochondrial); 9, β-oxidation; 10, citrate synthase; 11, adenylosuccinate synthetase; 12, adenylate deaminase. Abbreviations: AGC1, aspartate–glutamate carrier; ASCT, alanine, serine, cysteine, and threonine carrier; BAT, BCAA transporter (SLC25A4); BCAA, branched-chain amino acids; BCA-CoA, branched-chain acyl-CoA; BCKA, branched-chain keto acids; CAC, citric acid cycle; CS, carnitine system; EAAT, excitatory amino acid transporters; GLUT, glucose transporter; LAT1, large neutral amino acid transporter 1; MCT, monocarboxylate transporter; OA, oxaloacetate; OGC, 2-oxoglutarate carrier; PC, pyruvate carrier; PNC, purine-nucleotide cycle; Pyr, pyruvate; SNAT, sodium neutral amino acid transporter; 2-OG, 2-oxoglutarate.
Ijms 25 07037 g001
Ijms 25 07037 g002
Figure 2. Pathways of alanine and glutamine conversion to oxaloacetate in mitochondria and its delivery to the cytosol in the form of aspartate. 1, ALT (cytosolic); 2, pyruvate carboxylase; 3, AST (mitochondrial); 4, AST (cytosolic); 5, glutaminase; 6, GDH1(2); 7, enzymes converting 2-OG to malate; 8, malate dehydrogenase (mitochondrial); 9, PEPCK; 10, malate dehydrogenase (cytosolic); 11, ALT (mitochondrial); 12, pyruvate dehydrogenase; 13, 3-hydroxyacyl-CoA dehydrogenase; 14, citrate synthase. Abbreviations: AGC2, aspartate–glutamate carrier; CAC, citric acid cycle; CS, carnitine system; FA, fatty acids; Mal, malate; OA, oxaloacetate; OGC, 2-oxoglutarate carrier; PC, pyruvate carrier; PEP, phosphoenolpyruvate; Pyr, pyruvate; UCP2, uncoupling protein 2; 2-OG, 2-oxoglutarate.
Figure 2. Pathways of alanine and glutamine conversion to oxaloacetate in mitochondria and its delivery to the cytosol in the form of aspartate. 1, ALT (cytosolic); 2, pyruvate carboxylase; 3, AST (mitochondrial); 4, AST (cytosolic); 5, glutaminase; 6, GDH1(2); 7, enzymes converting 2-OG to malate; 8, malate dehydrogenase (mitochondrial); 9, PEPCK; 10, malate dehydrogenase (cytosolic); 11, ALT (mitochondrial); 12, pyruvate dehydrogenase; 13, 3-hydroxyacyl-CoA dehydrogenase; 14, citrate synthase. Abbreviations: AGC2, aspartate–glutamate carrier; CAC, citric acid cycle; CS, carnitine system; FA, fatty acids; Mal, malate; OA, oxaloacetate; OGC, 2-oxoglutarate carrier; PC, pyruvate carrier; PEP, phosphoenolpyruvate; Pyr, pyruvate; UCP2, uncoupling protein 2; 2-OG, 2-oxoglutarate.
Ijms 25 07037 g002
Ijms 25 07037 g003
Figure 3. Gluconeogenesis from alanine and glutamine in the liver and its relationship with urea synthesis. On the right is depicted the pathway of oxaloacetate synthesis from alanine; the pathway from glutamine is less significant under usual conditions. 1, ALT (cytosolic); 2, pyruvate carboxylase; 3, AST (mitochondrial); 4, AST (cytosolic); 5, glutaminase; 6, GDH1; 7, enzymes converting 2-OG to malate; 8, malate dehydrogenase (mitochondrial); 9, carbamoyl phosphate synthetase; 10, ornithine carbamoyltransferase; 11, argininosuccinate synthetase; 12, argininosuccinate lyase; 13, arginase; 14, fumarase; 15, malate dehydrogenase (cytosolic); 16, PEPCK; 17, N-acetylglutamate synthase; 18, ALT (mitochondrial). Abbreviations: AGC2, aspartate–glutamate carrier 2; AS, argininosuccinate; CAC, citric acid cycle; CP, carbamoyl phosphate; GluC, glutamate carrier; Mal, malate; NAG, N-acetylglutamate; OA, oxaloacetate; OGC, 2-oxoglutarate carrier; OrC, ornithine/citrulline carrier; PC, pyruvate carrier; PEP, phosphoenolypyruvate; PEPCK, phosphoenolypyruvate carboxykinase; Pyr, pyruvate; UC, urea cycle; UCP2, uncoupling protein 2; 2-OG, 2-oxoglutarate.
Figure 3. Gluconeogenesis from alanine and glutamine in the liver and its relationship with urea synthesis. On the right is depicted the pathway of oxaloacetate synthesis from alanine; the pathway from glutamine is less significant under usual conditions. 1, ALT (cytosolic); 2, pyruvate carboxylase; 3, AST (mitochondrial); 4, AST (cytosolic); 5, glutaminase; 6, GDH1; 7, enzymes converting 2-OG to malate; 8, malate dehydrogenase (mitochondrial); 9, carbamoyl phosphate synthetase; 10, ornithine carbamoyltransferase; 11, argininosuccinate synthetase; 12, argininosuccinate lyase; 13, arginase; 14, fumarase; 15, malate dehydrogenase (cytosolic); 16, PEPCK; 17, N-acetylglutamate synthase; 18, ALT (mitochondrial). Abbreviations: AGC2, aspartate–glutamate carrier 2; AS, argininosuccinate; CAC, citric acid cycle; CP, carbamoyl phosphate; GluC, glutamate carrier; Mal, malate; NAG, N-acetylglutamate; OA, oxaloacetate; OGC, 2-oxoglutarate carrier; OrC, ornithine/citrulline carrier; PC, pyruvate carrier; PEP, phosphoenolypyruvate; PEPCK, phosphoenolypyruvate carboxykinase; Pyr, pyruvate; UC, urea cycle; UCP2, uncoupling protein 2; 2-OG, 2-oxoglutarate.
Ijms 25 07037 g003
Ijms 25 07037 g004
Figure 4. Heterogeneity of periportal and perivenous hepatocytes in glutamine and ammonia metabolism: 1, glutaminase; 2, GDH1; 3, carbamoyl phosphate synthetase; 4, AST; 5, glutamine synthetase. Abbreviations: OA, oxaloacetate; CP, carbamoyl phosphate; SNAT, sodium neutral amino acid transporter; UC, urea cycle; 2-OG, 2-oxoglutarate.
Figure 4. Heterogeneity of periportal and perivenous hepatocytes in glutamine and ammonia metabolism: 1, glutaminase; 2, GDH1; 3, carbamoyl phosphate synthetase; 4, AST; 5, glutamine synthetase. Abbreviations: OA, oxaloacetate; CP, carbamoyl phosphate; SNAT, sodium neutral amino acid transporter; UC, urea cycle; 2-OG, 2-oxoglutarate.
Ijms 25 07037 g004
Ijms 25 07037 g005
Figure 5. Gluconeogenesis from glutamine and supposed pathways of alanine metabolism in kidneys. The main pathways by which the carbon skeleton of glutamine is converted to oxaloacetate are depicted on the right side. 1, ALT (cytosolic); 2, pyruvate carboxylase; 3, AST (mitochondrial); 4, AST (cytosolic); 5, glutaminase; 6, GDH2; 7, enzymes converting 2-OG to malate; 8, malate dehydrogenase (mitochondrial); 9, PEPCK; 10, malate dehydrogenase (cytosolic); 11, ALT (mitochondrial); 12, lactate dehydrogenase; 13, carbonic anhydrase. Abbreviations: AGC2, aspartate–glutamate carrier 2; B0AT1, broad neutral amino acid transporter 1; CAC, citric acid cycle; GLUT, glucose transporter; LAT, large neutral amino acid transporter; Mal, malate; MCT, monocarboxylate transporter; NBC, Na+:HCO3− cotransporter; NHE, Na+/H+ exchanger; OA, oxaloacetate; OGC, oxoglutarate carrier; PC, pyruvate carrier; Pyr, pyruvate; SGLT, sodium–glucose-linked transporter; SNAT, sodium neutral amino acid transporter; 2-OG, 2-oxoglutarate.
Figure 5. Gluconeogenesis from glutamine and supposed pathways of alanine metabolism in kidneys. The main pathways by which the carbon skeleton of glutamine is converted to oxaloacetate are depicted on the right side. 1, ALT (cytosolic); 2, pyruvate carboxylase; 3, AST (mitochondrial); 4, AST (cytosolic); 5, glutaminase; 6, GDH2; 7, enzymes converting 2-OG to malate; 8, malate dehydrogenase (mitochondrial); 9, PEPCK; 10, malate dehydrogenase (cytosolic); 11, ALT (mitochondrial); 12, lactate dehydrogenase; 13, carbonic anhydrase. Abbreviations: AGC2, aspartate–glutamate carrier 2; B0AT1, broad neutral amino acid transporter 1; CAC, citric acid cycle; GLUT, glucose transporter; LAT, large neutral amino acid transporter; Mal, malate; MCT, monocarboxylate transporter; NBC, Na+:HCO3− cotransporter; NHE, Na+/H+ exchanger; OA, oxaloacetate; OGC, oxoglutarate carrier; PC, pyruvate carrier; Pyr, pyruvate; SGLT, sodium–glucose-linked transporter; SNAT, sodium neutral amino acid transporter; 2-OG, 2-oxoglutarate.
Ijms 25 07037 g005
Ijms 25 07037 g007
Figure 7. Supposed interactions among muscles, liver, kidneys, and small intestine that ensure alanine and glutamine supply for the needs of gluconeogenesis.
Figure 7. Supposed interactions among muscles, liver, kidneys, and small intestine that ensure alanine and glutamine supply for the needs of gluconeogenesis.
Ijms 25 07037 g007
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Holeček, M. Origin and Roles of Alanine and Glutamine in Gluconeogenesis in the Liver, Kidneys, and Small Intestine under Physiological and Pathological Conditions. Int. J. Mol. Sci. 2024, 25, 7037. https://doi.org/10.3390/ijms25137037

AMA Style

Holeček M. Origin and Roles of Alanine and Glutamine in Gluconeogenesis in the Liver, Kidneys, and Small Intestine under Physiological and Pathological Conditions. International Journal of Molecular Sciences. 2024; 25(13):7037. https://doi.org/10.3390/ijms25137037

Chicago/Turabian Style

Holeček, Milan. 2024. "Origin and Roles of Alanine and Glutamine in Gluconeogenesis in the Liver, Kidneys, and Small Intestine under Physiological and Pathological Conditions" International Journal of Molecular Sciences 25, no. 13: 7037. https://doi.org/10.3390/ijms25137037

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop